IDEAYA Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Catherine J. Mackey, Ph.D.

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Catherine J. Mackey, Ph.D.”): 70,281,521 for, 2,734,974 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 32,881,085 for, 550,344 withheld, 9 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: M. Garret Hampton, Ph.D.

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: M. Garret Hampton, Ph.D.”): 56,718,637 for, 16,297,858 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 31,284,057 for, 2,143,547 withheld, 3,834 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Yujiro S. Hata

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Yujiro S. Hata”): 70,546,418 for, 2,470,077 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 32,881,087 for, 550,344 withheld, 7 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and

IDEAYA Biosciences, Inc.’s own tally for this item (“3. The non-binding, advisory vote to approve the compensation of the Company's named executive officers”): 64,269,756 for, 8,349,131 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 72 managers: 27,992,585 for, 5,444,088 against, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 231 managers: 57,775,379 for, 7,066,904 against, 24,284 abstained, 258 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;

IDEAYA Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending”): 82,579,758 for, 141,240 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 33,436,605 for, 632 against, 1 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.